Thus, RANKL inhibition using an approved drug might be a feasible strategy to, for the first time, prevent breast cancer in BRCA1-mutation carriers and possibly in other women at high risk for developing breast cancer. This evidence concerns the gene TNFSF11 and breast carcinoma.